2026 EHA | Phase III study of tafasitamab combination therapy in previously untreated DLBCL shows significantly prolonged progression-free survival

InnoCare Pharma Limited (HKEX: 09969; SSE: 688428) today announced that results from the global Phase III frontMIND study of tafasitamab combination therapy were presented as a late-breaking oral presentation at the Plenary Session of the 2026 European Hematology Association (EHA) Annual Meeting. The results demonstrated that, compared with the current first-line standard regimen R-CHOP, the tafasitamab plus lenalidomide and R-CHOP regimen (Tafa-Len-R-CHOP) significantly improved progression-free survival (PFS) with strong statistical significance and clinical relevance, offering a potential new first-line standard of care for patients with high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL).

Plenary Session Oral Presentation

Phase III frontMIND Study Results of Tafasitamab Plus Lenalidomide and R-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (Abstract #: S101)

This study is a randomized, double-blind, placebo-controlled international multicenter trial designed to identify a first-line treatment regimen with superior efficacy and safety compared to the R-CHOP regimen.

In terms of efficacy, after a median follow-up of 35.2 months, Tafa-Len-R-CHOP reduced the risk of disease progression or death by 25% compared to R-CHOP (HR=0.75, P=0.0194), improved the 2-year progression-free survival (PFS) rate by 8.2%, and the 3-year PFS rate by 6.6%, meeting the primary endpoint.

Consistent trends in progression-free survival benefit were observed across all pre-specified subgroups, including lymphoma subtypes confirmed by central laboratory testing and molecular subtypes defined by cell-of-origin (COO)—namely, activated B-cell-like (ABC) and germinal center B-cell-like (GCB).

Regarding safety, the Tafa-Len-R-CHOP regimen was generally well tolerated, with a safety profile consistent with the expected adverse event spectrum when adding tafasitamab and lenalidomide to the R-CHOP backbone. Additional adverse events associated with Tafa-Len-R-CHOP were manageable and did not interfere with the full administration of the base R-CHOP regimen.

Regardless of cell-of-origin (COO) molecular subtype, Tafa-Len-R-CHOP has the potential to become a new standard first-line treatment for patients with high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL).

19K Views